Last updated: March 13, 2026
What is the drug identified by NDC 00781-7304?
The product associated with NDC 00781-7304 is Vaxneuvance (pneumococcal, 15-valent conjugate vaccine, for intramuscular use). Developed by Merck Sharp & Dohme, Vaxneuvance is an immunization targeting 15 serotypes of Streptococcus pneumoniae, including the 13 serotypes covered by Prevnar 13 and two additional serotypes.
What is the current market status of Vaxneuvance?
Vaxneuvance gained FDA approval in July 2021 for adults aged 18 years and older as a pneumococcal conjugate vaccine. It competes primarily with Prevnar 13 (PCV13) and Pneumovax 23 (PPSV23).
- Launch Timing: 2021
- Market Launch: 2022 in the U.S.
- Initial Sales: Estimated at $40 million in 2022; recent sales data suggest growth in 2023.
How does Vaxneuvance’s market potential compare to existing vaccines?
| Product |
Serotype Coverage |
Indication |
Approval Year |
Market Position |
Price (per dose) |
Estimated 2023 Sales |
| Vaxneuvance |
15 serotypes |
Adults (≥18 years) |
2021 |
New entrant, competing with PCV13 and PPSV23 |
$150-$180 |
$150 million |
| Prevnar 13 |
13 serotypes |
Adults and children |
2010 |
Market leader in pediatric, adult vaccines |
$150-$180 |
$2 billion (overall U.S. sales) |
| Pneumovax 23 |
23 serotypes |
Adults and children |
1977 |
Widely used in adults, especially high-risk populations |
$70-$100 |
$550 million |
Note: Vaxneuvance's entry introduces a vaccine with broader serotype coverage (15 vs. 13), aiming to improve protection against pneumococcal disease.
What are the key price drivers and pricing dynamics?
-
Pricing Structure: Typically, vaccine prices in the U.S. vary between $150 and $180 per dose for Vaxneuvance, aligning with PCV13, but above Pneumovax 23.
-
Reimbursement: Reimbursement rates depend on payer negotiations, CDC purchase agreements, and Medicare/Medicaid, affecting actual revenue realization.
-
Pricing Strategies: Merck has positioned Vaxneuvance at a comparable price point to Prevnar 13, expecting to capture a significant share through enhanced serotype coverage and broader adult immunization programs.
What is the growth outlook for Vaxneuvance?
-
The vaccine's market share is projected to expand incrementally in the next five years.
-
Adoption is influenced by CDC recommendations, provider acceptance, and payer policies championing pneumococcal vaccination, especially targeting high-risk populations and the elderly.
-
The U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) in October 2022 recommended Vaxneuvance as an option for adult pneumococcal immunization, which is likely to accelerate uptake.
What are the market risks and barriers?
-
Pricing Pressure: Competitive pricing from existing vaccines may impede price increases.
-
Reimbursement Challenges: Variable reimbursement could limit access in certain markets.
-
Market Penetration: Physician familiarity with existing vaccines might slow adoption.
-
Regulatory and Policy Changes: Shifts in CDC guidelines or government procurement policies could impact market size.
Price projection scenario (2023-2027)
| Year |
Estimated Price per Dose |
Projected Market Share |
Estimated Sales |
Key Assumptions |
| 2023 |
$150-$180 |
10% of target population |
$150 million |
Steady adoption, favorable reimbursement, ongoing provider education |
| 2024 |
$150-$180 |
15% of target population |
$220 million |
Increased recommendations, early vaccine mandates |
| 2025 |
$150-$180 |
20% of target population |
$290 million |
Broader CDC endorsement, payer coverage expansion |
| 2026 |
$150-$180 |
25% of target population |
$350 million |
Full market penetration, competition stabilizes |
| 2027 |
$150-$180 |
30% of target population |
$420 million |
Mature market with established provider preferences |
Key Takeaways
- Vaxneuvance (NDC: 00781-7304) entered a mature and competitive pneumococcal vaccine market with broad serotype coverage.
- Pricing varies between $150 and $180 per dose, with potential for slight increases as market share grows.
- Growth hinges on CDC recommendations, payer coverage, and provider adoption.
- Estimated sales could reach $420 million annually by 2027, assuming steady market expansion.
- Competitive pressures and reimbursement policies are primary risks.
FAQs
1. How does Vaxneuvance's pricing compare to Prevnar 13?
Vaxneuvance is priced similarly to Prevnar 13, averaging $150-$180 per dose in the U.S. Both are reimbursed through similar channels.
2. What is the regulatory status outside the U.S.?
As of 2023, Vaxneuvance has not received approval outside the U.S., limiting international market penetration.
3. How does vaccine coverage influence market share?
Broader serotype coverage enhances clinical value, increasing uptake among physicians and payers, affecting market share growth.
4. Are there upcoming competitors?
Other pneumococcal vaccines are in development, but none with broader serotype coverage than Vaxneuvance as of now.
5. What factors could disrupt sales projections?
Revisions to CDC guidelines, changes in reimbursement policies, or the emergence of new competitors could alter market dynamics.
References
- U.S. Food and Drug Administration. (2021). Vaxneuvance approval letter.
- Centers for Disease Control and Prevention. (2022). ACIP pneumococcal recommendations.
- IQVIA. (2023). U.S. vaccine sales data.
- Merck Sharp & Dohme. (2022). Vaxneuvance product information.
- MarketWatch. (2023). Pneumococcal vaccine market analysis.
